Covis Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Zug Switzerland (2011)
Status: Acquired by Advanz Pharma (2015)

Organization Overview

First Clinical Trial
2016
NCT02688270
First Marketed Drug
2011
digoxin (lanoxin)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

COVIS | COVIS PHARMA BV | Covis Pharma S.à.r.l.

Active Ingredients

Marketed Drugs (12)

Key: Covis (10) Acquired (2)

aclidinium (tudorza pressair) (2012)

ciclesonide (alvesco) (2006)

digoxin (lanoxin) (1954 NDA)

ferumoxytol (feraheme) (2009)

formoterol (foradil) (2019)

hydroxyprogesterone (Delalutin) (2011)

lovastatin (mevacor) (2002)

nisoldipine (sular) (1995 NDA)

omeprazole (prilosec) (2008)

riluzole (rilutek) (1995)

sotalol (betapace) (1992)

tizanidine (zanaflex) (1996 NDA)

Drugs in Phase 4 Trials (5)

Key: Covis (0) Acquired (5)

acetylsalicylic acid (aspirin) (1 trial)

bremelanotide (Vyleesi) (2 trials)

ferrous sulfate (6 trials)

ferumoxytol (feraheme) (28 trials)

iron dextran (INFeD) (3 trials)

Drugs in Phase 3 Trials (11)

Key: Covis (1) Acquired (10)

butoconazole (Femstat) (2 trials)

ciclesonide (alvesco) (1 trial)

clindamycin (cleocin) (2 trials)

estradiol (progynon depot) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

ferrous fumarate (1 trial)

hydroxyprogesterone (Delalutin) (4 trials)

iron sucrose (venofer) (2 trials)

prasterone (intrarosa) (3 trials)

progestin (1 trial)

vitamin c (2 trials)

Drugs in Phase 2 Trials (15)

Key: Covis (1) Acquired (14)

autologous mononuclear stem cell (2 trials)

autologous umbilical cord blood (3 trials)

carbomer (1 trial)

ciraparantag (8 trials)

danazol (danocrine) (1 trial)

dehydroepiandrosterone (1 trial)

digoxin immune fab (ovine) (DigiFab) (1 trial)

diphenhydramine (benadryl) (1 trial)

epoetin (Epogen) (1 trial)

glycerin (1 trial)

lidocaine (xylocaine) (1 trial)

mineral oil (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

palm oil (1 trial)

polycarbophil (1 trial)

Drugs in Phase 1 Trials (4)

Key: Covis (0) Acquired (4)

autologous adipose-derived mesenchymal stem cells (1 trial)

insulin lispro (humalog) (1 trial)

moxifloxacin (avelox) (1 trial)

ondansetron (zofran) (1 trial)

Drugs in Other Trials (1)

Key: Covis (0) Acquired (1)

sodium chloride (1 trial)

Indications

Approved Indications


 

Atrial Fibrillation

Heart Failure

Hypertension

Muscle Spasticity

Experimental Indications (Clinical Trials, Phases 1-4)


 

Connective Tissue Diseases (Phase 2)

Neoplasm Metastasis (Phase 2)

Raynaud Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 63
  • # of Trial APIs: 36